Login

Switch On Your HIV Smarts.

Author Archives: Emily Land

An “Improved Backbone” for New HIV Regimens Now Under FDA Review

An “Improved Backbone” for New HIV Regimens Now Under FDA Review

, by Emily Land

A new version of tenofovir may result in a better-tolerated replacement for Truvada. Read More

PrEP and Drug Resistance: Cause for Concern?

PrEP and Drug Resistance: Cause for Concern?

, by Emily Land

A new study examines HIV drug resistance associated with PrEP, and what it could mean as this highly-effective prevention strategy becomes more prevalent. Read More

Compound Found to Block HIV Receptors in Monkeys

Compound Found to Block HIV Receptors in Monkeys

, by Emily Land

A recent New York Times article explains the science behind a new advance that could contribute to a successful HIV vaccine. Read More

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

Dolutegravir Shows Promise as Part of First-Line HIV Therapy

, by Emily Land

An integrase inhibitor fared well in a head-to-head comparison with a protease inhibitor regimen for people just starting ART. Find out why this is surprising and what it could mean for treatment naïve people with high viral loads. Read More

Supervisor Wiener: Reclassifying HIV Drugs as “Specialty” is Discriminatory

Supervisor Wiener: Reclassifying HIV Drugs as “Specialty” is Discriminatory

, by Emily Land

Placing HIV and hepatitis C drugs on “specialty” tiers affects their access and affordability. Supervisor Scott Wiener called attention to this issue during a recent San Francisco hearing.
Read More